Which has higher earnings and valuation, ORPH or APTA?

Open Orphan has higher revenue and earnings than Aptamer Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Open Orphan £34.71M 0.00 N/A N/A N/A Aptamer Group £1.38M 13.79 -£14.17M -£0.11 N/A

Is REDX or APTA more profitable?

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redx Pharma N/A -180.80% -43.95% Aptamer Group -178.52% -135.35% -44.96%

Do analysts recommend HVO or APTA?

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 67.60%. Given hVIVO's stronger consensus rating and higher probable upside, research analysts plainly believe hVIVO is more favorable than Aptamer Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Aptamer Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, HVO or APTA?

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.32 £17.84M -£0.87 N/A Aptamer Group £1.38M 13.79 -£14.17M -£0.11 N/A

Is HVO or APTA more profitable?

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% Aptamer Group -178.52% -135.35% -44.96%

Aptamer Group (APTA) Competitors

GBX 0.55 +0.05 (+10.00%)

As of 11:40 AM Eastern

Compare

APTA vs. ORPH, REDX, HVO, ETX, and COIL

Should you buy Aptamer Group stock or one of its competitors? MarketBeat compares Aptamer Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aptamer Group include Open Orphan (ORPH), Redx Pharma (REDX), hVIVO (HVO), e-therapeutics (ETX), and Roquefort Therapeutics (COIL). These companies are all part of the "biotechnology" industry.

How does Aptamer Group compare to Open Orphan?

Open Orphan (LON:ORPH) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

Open Orphan has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Open Orphan's return on equity of 0.00% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Open Orphan	N/A	N/A	N/A
Aptamer Group	-178.52%	-135.35%	-44.96%

Open Orphan has higher revenue and earnings than Aptamer Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Open Orphan	£34.71M	0.00	N/A	N/A	N/A
Aptamer Group	£1.38M	13.79	-£14.17M	-£0.11	N/A

3.0% of Aptamer Group shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Open Orphan's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Open Orphan	Neutral
Aptamer Group	Neutral

Summary

Open Orphan beats Aptamer Group on 4 of the 7 factors compared between the two stocks.

How does Aptamer Group compare to Redx Pharma?

Redx Pharma (LON:REDX) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Redx Pharma has a beta of -0.53, meaning that its stock price is 153% less volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.916, meaning that its stock price is 8% less volatile than the broader market.

Aptamer Group has lower revenue, but higher earnings than Redx Pharma. Aptamer Group is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A
Aptamer Group	£1.38M	13.79	-£14.17M	-£0.11	N/A

Redx Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Aptamer Group's return on equity of -135.35% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redx Pharma	N/A	-180.80%	-43.95%
Aptamer Group	-178.52%	-135.35%	-44.96%

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 3.0% of Aptamer Group shares are held by institutional investors. 18.4% of Redx Pharma shares are held by company insiders. Comparatively, 7.3% of Aptamer Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Redx Pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
Redx Pharma	Neutral
Aptamer Group	Neutral

Summary

Redx Pharma beats Aptamer Group on 6 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to hVIVO?

hVIVO (LON:HVO) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings, risk and media sentiment.

hVIVO has higher revenue and earnings than Aptamer Group. hVIVO is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.32	£17.84M	-£0.87	N/A
Aptamer Group	£1.38M	13.79	-£14.17M	-£0.11	N/A

In the previous week, hVIVO had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Aptamer Group. hVIVO's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company	Overall Sentiment
hVIVO	Neutral
Aptamer Group	Neutral

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 3.0% of Aptamer Group shares are owned by institutional investors. 4.9% of hVIVO shares are owned by insiders. Comparatively, 7.3% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

hVIVO has a beta of 1.685, suggesting that its stock price is 69% more volatile than the broader market. Comparatively, Aptamer Group has a beta of 0.916, suggesting that its stock price is 8% less volatile than the broader market.

hVIVO has a net margin of -12.48% compared to Aptamer Group's net margin of -178.52%. hVIVO's return on equity of -14.65% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
Aptamer Group	-178.52%	-135.35%	-44.96%

hVIVO currently has a consensus price target of GBX 15, suggesting a potential upside of 67.60%. Given hVIVO's stronger consensus rating and higher probable upside, research analysts plainly believe hVIVO is more favorable than Aptamer Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Aptamer Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

hVIVO beats Aptamer Group on 11 of the 15 factors compared between the two stocks.

How does Aptamer Group compare to e-therapeutics?

Aptamer Group (LON:APTA) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

e-therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	13.79	-£14.17M	-£0.11	N/A
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A

Aptamer Group has a beta of 0.916, suggesting that its share price is 8% less volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
e-therapeutics	Neutral

e-therapeutics has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. e-therapeutics' return on equity of -38.75% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
e-therapeutics	N/A	-38.75%	-29.10%

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 26.5% of e-therapeutics shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by insiders. Comparatively, 59.4% of e-therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

e-therapeutics beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Aptamer Group compare to Roquefort Therapeutics?

Aptamer Group (LON:APTA) and Roquefort Therapeutics (LON:COIL) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

3.0% of Aptamer Group shares are owned by institutional investors. Comparatively, 1.2% of Roquefort Therapeutics shares are owned by institutional investors. 7.3% of Aptamer Group shares are owned by company insiders. Comparatively, 36.2% of Roquefort Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Roquefort Therapeutics has lower revenue, but higher earnings than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aptamer Group	£1.38M	13.79	-£14.17M	-£0.11	N/A
Roquefort Therapeutics	N/A	N/A	-£1.52M	-£21.90	N/A

In the previous week, Roquefort Therapeutics had 1 more articles in the media than Aptamer Group. MarketBeat recorded 1 mentions for Roquefort Therapeutics and 0 mentions for Aptamer Group. Aptamer Group's average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aptamer Group	Neutral
Roquefort Therapeutics	Neutral

Aptamer Group has a beta of 0.916, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its stock price is 95% less volatile than the broader market.

Aptamer Group has a net margin of -178.52% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.30% beat Aptamer Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aptamer Group	-178.52%	-135.35%	-44.96%
Roquefort Therapeutics	-57,057.07%	-18.30%	-15.86%

Summary

Roquefort Therapeutics beats Aptamer Group on 6 of the 11 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APTA vs. The Competition

Export

Metric	Aptamer Group	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£19.00M	£436.28M	£6.48B	£2.71B
Dividend Yield	N/A	3.86%	2.67%	6.16%
P/E Ratio	-5.00	3.18	24.56	366.28
Price / Sales	13.79	6,656.31	531.17	86,890.05
Price / Cash	N/A	13.13	26.99	27.85
Price / Book	2.57	87.10	10.52	7.71
Net Income	-£14.17M	-£96.07M	£3.56B	£5.89B
7 Day Performance	4.76%	-2.20%	-0.98%	-0.75%
1 Month Performance	-9.98%	0.13%	1.27%	1.84%
1 Year Performance	71.88%	52.82%	21.32%	71.71%

Aptamer Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APTA Aptamer Group	N/A	GBX 0.55 +10.0%	N/A	+56.3%	£19.00M	£1.38M	N/A	37	Gap Up
ORPH Open Orphan	N/A	N/A	N/A	N/A	£67.09M	£34.71M	N/A	179
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
HVO hVIVO	1.8981 of 5 stars	GBX 8.25 +1.9%	GBX 15 +81.8%	-22.3%	£56.79M	£46.77M	N/A	N/A	Gap Up
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:APTA) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aptamer Group (APTA) Competitors

APTA vs. ORPH, REDX, HVO, ETX, and COIL

How does Aptamer Group compare to Open Orphan?

Summary

How does Aptamer Group compare to Redx Pharma?

Summary

How does Aptamer Group compare to hVIVO?

Summary

How does Aptamer Group compare to e-therapeutics?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aptamer Group (APTA) Competitors

APTA vs. ORPH, REDX, HVO, ETX, and COIL

How does Aptamer Group compare to Open Orphan?

Is ORPH or APTA more profitable?

Which has higher earnings and valuation, ORPH or APTA?

Do insiders & institutionals believe in ORPH or APTA?

Does the media refer more to ORPH or APTA?

Summary

How does Aptamer Group compare to Redx Pharma?

Which has more risk and volatility, REDX or APTA?

Which has stronger earnings and valuation, REDX or APTA?

Is REDX or APTA more profitable?

Do institutionals & insiders hold more shares of REDX or APTA?

Does the media favor REDX or APTA?

Summary

How does Aptamer Group compare to hVIVO?

Which has preferable valuation & earnings, HVO or APTA?

Does the media favor HVO or APTA?

Do institutionals & insiders have more ownership in HVO or APTA?

Which has more risk and volatility, HVO or APTA?

Is HVO or APTA more profitable?

Do analysts recommend HVO or APTA?

Summary

How does Aptamer Group compare to e-therapeutics?

Which has stronger earnings and valuation, APTA or ETX?

Which has more risk & volatility, APTA or ETX?

Does the media refer more to APTA or ETX?

Is APTA or ETX more profitable?

Do insiders and institutionals hold more shares of APTA or ETX?

Summary

How does Aptamer Group compare to Roquefort Therapeutics?

Do institutionals and insiders have more ownership in APTA or COIL?

Which has preferable valuation and earnings, APTA or COIL?

Does the media favor APTA or COIL?

Which has more volatility and risk, APTA or COIL?

Is APTA or COIL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APTA vs. The Competition

Aptamer Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools